Skip to main content
. 2010 Dec 31;43(4):310–316. doi: 10.5115/acb.2010.43.4.310

Fig. 5.

Fig. 5

Amorphigenin inhibits RANKL-mediated c-Fos and NFATc1 expression. BMMs were pretreated with or without amorphigenin and stimulated with RANKL (100 ng/ml) for the indicated times. The cells were lysed in lysis buffer. c-Fos, NFATc1, or actin proteins were detected by Western blotting with an anti-c-fos, and anti-NFATc1, or anti-actin-antibody, respectively.